NO20075095L - Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse - Google Patents

Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse

Info

Publication number
NO20075095L
NO20075095L NO20075095A NO20075095A NO20075095L NO 20075095 L NO20075095 L NO 20075095L NO 20075095 A NO20075095 A NO 20075095A NO 20075095 A NO20075095 A NO 20075095A NO 20075095 L NO20075095 L NO 20075095L
Authority
NO
Norway
Prior art keywords
crystals
preparation
methyl
propylpyrrolo
cyclopropylamino
Prior art date
Application number
NO20075095A
Other languages
English (en)
Norwegian (no)
Inventor
Mary F Malley
Zhongping Shi
Soonjin Kim
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20075095L publication Critical patent/NO20075095L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO20075095A 2005-04-18 2007-10-09 Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse NO20075095L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67225505P 2005-04-18 2005-04-18
PCT/US2006/014504 WO2006113682A1 (en) 2005-04-18 2006-04-18 Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein

Publications (1)

Publication Number Publication Date
NO20075095L true NO20075095L (no) 2007-11-15

Family

ID=36693144

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075095A NO20075095L (no) 2005-04-18 2007-10-09 Metode for fremstilling av salter av 4-[[5-[(cyklopropylamino)karbonyl]-2-Methylphenyl]Amino]-Methyl-N-Propylpyrrolo[2,1-F][1,2,4]triazin-6-karboksamid og nye stabile varianter av disse

Country Status (12)

Country Link
US (3) US20060235020A1 (de)
EP (1) EP1874778B1 (de)
JP (1) JP5047160B2 (de)
CN (1) CN101198610B (de)
AR (1) AR053586A1 (de)
AT (1) ATE452894T1 (de)
DE (1) DE602006011295D1 (de)
ES (1) ES2336363T3 (de)
NO (1) NO20075095L (de)
PE (1) PE20061429A1 (de)
TW (1) TW200716126A (de)
WO (1) WO2006113682A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1497019B1 (de) * 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazin-anilin-verbindungen als kinaseinhibitoren
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
EP2376491B1 (de) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazine als alk- und jak2-inhibitoren
US9511071B2 (en) * 2010-08-18 2016-12-06 Emory University Compounds and compositions for ossification and methods related thereto
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
CN104003990B (zh) * 2013-02-21 2017-09-15 江苏先声药业有限公司 杂环胺类Hedgehog信号通路抑制剂
WO2015112048A1 (en) * 2014-01-24 2015-07-30 Huawei Technologies Co., Ltd. Method and device for cross-polarization interference suppression
WO2016154362A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
GB2533833B (en) * 2015-06-22 2016-12-14 Univ Bristol Wireless ultrasound sensor with two induction coils
CN105651804B (zh) * 2016-03-11 2017-05-17 山西大学 一种慢性萎缩性胃炎大鼠模型的评价方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
WO2020209868A1 (en) * 2019-04-12 2020-10-15 Bruker Axs, Inc. A system and method for diffraction-based structure determination with simultaneous processing modules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) * 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
TR199801361T2 (xx) * 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
AR037061A1 (es) * 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
WO1999001452A1 (en) * 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1497019B1 (de) * 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Pyrrolo-triazin-anilin-verbindungen als kinaseinhibitoren
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors

Also Published As

Publication number Publication date
TW200716126A (en) 2007-05-01
EP1874778A1 (de) 2008-01-09
ES2336363T3 (es) 2010-04-12
WO2006113682A1 (en) 2006-10-26
CN101198610B (zh) 2012-06-13
JP2008538373A (ja) 2008-10-23
US20120108594A1 (en) 2012-05-03
PE20061429A1 (es) 2006-12-17
US20090312331A1 (en) 2009-12-17
ATE452894T1 (de) 2010-01-15
US20060235020A1 (en) 2006-10-19
EP1874778B1 (de) 2009-12-23
AR053586A1 (es) 2007-05-09
DE602006011295D1 (de) 2010-02-04
JP5047160B2 (ja) 2012-10-10
CN101198610A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
TW200716126A (en) Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl] amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
AU2005314155C1 (en) Method for preparing N-phenylpyrazole-1-carboxamides
CA2422708A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
RU2003105900A (ru) Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью
CA2745266C (en) Stem cell cultures
CN104936961B (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
WO2020140005A8 (en) 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN104411700B (zh) 4-[5-(吡啶-4-基)-1h-1,2,4-三唑-3-基]吡啶-2-腈的多晶型及其制造方法
CA2578122A1 (en) Pyrimidine derivatives
PH12013500157A1 (en) SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE
NO20076424L (no) N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser
JP2004518763A5 (de)
HRP20110639T1 (hr) 4-metil-n-[3-4(-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamid-monohidroklorid-monohidratna sol
ATE401066T1 (de) Methoden zur behandlung der essstörungen
NO20073114L (no) Amidforbindelse
NO974844L (no) Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser
NO20055219L (no) Nye forbindelser
EP1717288A3 (de) Aminbasierende Gashydratinhibitoren
NO20054206L (no) Bifenylderivater
CA2680246A1 (en) Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same
NO20062954L (no) Pyrazolylderivater i form av legemidler for behandling av av akutt eller kronisk neuronal regresjon
WO2015096604A1 (zh) 一种米拉贝隆有关物质或其盐、其制备方法和用途
Wang et al. Synthesis and antifungal activity evaluation of novel substituted pyrimidine‐5‐carboxamides bearing the pyridine moiety
CA2653666A1 (en) Aryl-substituted heterocycles and their use
EP0343307A1 (de) 4-Piperidinalkanamin-Derivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application